Current Stem Cell Delivery Methods for Myocardial Repair

Table 3

Intracoronary artery administration studies.

Study	No. of patients	Cell type	No. of cells	Outcome
Strauer et al. (2002) [102]	20	ABMMNC	2.8 × 10^7	No significant LVEF improvement versus control
Chen et al. (2004) [135]	69	SMB	6 × 10^10	Improvement in LVEF
Strauer et al. (2005) [136]	36	ABMMNC	9 × 10^7	Improvement in LVEF
Erbs et al. (2005) [137]	26	CPC	7 × 10^7	No significant LVEF improvement versus control
Bartunek et al. (2005) [138]	35	CD133 + BMC	1.3 × 10^7	No significant LVEF improvement versus control
Katritsis et al. (2005) [139]	22	MSC/EPC	3 × 10^6	No significant LVEF improvement versus control
Ruan et al. (2005) [140]	20	BMC	N/A	Improvement in LVEF
Assmus et al. (2006) [141]	51	ABMMNC	2 × 10^8	Improvement in LVEF
Meluzín et al. (2006) [142]	66	ABMMNC	1 × 10^8	Improvement in LVEF
Schächinger et al. (2006) [143]	204	ABMMNC	2.4 × 10^8	Decreased mortality
Ge et al. (2006) [144]	20	ABMMNC	4 × 10^7	No significant LVEF improvement versus control
Janssens et al. (2006) [145]	67	ABMMNC	1.7 × 10^8	No significant LVEF improvement versus control
Lunde et al. (2006) [146]	100	ABMMNC	8.7 × 10^7	Improvement in LVEF
Meyer et al. (2006) [147]	60	ABMMNC	2.5 × 10^9	No significant LVEF improvement versus control
Assmus et al. (2006) [141]	47	CPC	2 × 10^7	No significant LVEF improvement versus control
Schächinger et al. (2006) [143]	204	ABMMNC	2.4 × 10^8	Improvement in LVEF
Won et al. (2006) [126]	82	CPC	1.4 × 10^9	No significant LVEF improvement versus control
Li et al. (2007) [146]	70	CPC	7.3 × 10^7	Improvement in LVEF
Chen et al. (2006) [148]	48	SMB	5 × 10^6	No significant LVEF improvement versus control
Meluzín et al. (2008) [149]	60	ABMMNC	1 × 10^8	Improvement in LVEF
Tatsumi et al. (2007) [150]	54	CPC	5 × 10^9	Improvement in LVEF
Choi et al. (2007) [151]	73	CPC	2 × 10^9	No significant LVEF improvement versus control
Herbots et al. (2009) [152]	33/34	BMC	N/A	Better recovery of LV function
Beitnes et al. (2009) [153]	50/50	BMC	6.8 × 10^7	Improvement in exercise tolerance
Plewka et al. (2009) [154]	40/20	BMC	1.44 × 10^8	Improvement in LV function
Tendera et al. (2009) [155]	80/40	BMC	1.78 × 10^8	Longer delay between symptoms and revascularization
Strauer et al. (2010) [156]	191/200	BMC	6.6 × 10^7	Improvement in LV function
Traverse et al. (2010) [157]	30/10	BMC	1 × 10^8	Favorable effect on LV modeling
Quyyumi et al. (2011) [158]	16/15	CD34 + BMC	5, 10, and 15 × 10^6	Dose dependent LV function improvement

ABMMNC: autologous bone marrow mononuclear cells; BMC: bone marrow cells; CPC: cardiac progenitor cells; EPC: endothelial progenitor cells; LVEF: left ventricular ejection fraction; MSC: mesenchymal stem cells; SMB: skeletal myoblasts; results combined from two reviews.